Exact Sciences Corporation (NASDAQ:EXAS) has a beta value of 1.27 and has seen 1,133,636 shares traded in the last trading session. The company, currently valued at $21.23 Billion, closed the last trade at $125.53 per share which meant it lost -$6.29 on the day or -4.77% during that session. The EXAS stock price is -27.09% off its 52-week high price of $159.54 and 51.37% above the 52-week low of $61.05. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.77 Million shares traded. The 3-month trading volume is 1.87 Million shares.
The consensus among analysts is that Exact Sciences Corporation (EXAS) is an Overweight stock at the moment, with a recommendation rating of 1.6. 1 analysts rate the stock as a Sell, while 1 rate it as Overweight. 2 out of 18 have rated it as a Hold, with 14 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$1.03.
Exact Sciences Corporation (NASDAQ:EXAS) trade information
Despite being -4.77% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Apr 27 when the EXAS stock price touched $140.18 or saw a rise of 10.45%. Year-to-date, Exact Sciences Corporation shares have moved -5.25%, while the 5-day performance has seen it change -9.87%. Over the past 30 days, the shares of Exact Sciences Corporation (NASDAQ:EXAS) have changed -5.32%. Short interest in the company has seen 9.73 Million shares shorted with days to cover at 5.2.
Wall Street analysts have a consensus price target for the stock at $170.63, which means that the shares’ value could jump 35.93% from current levels. The projected low price target is $154 while the price target rests at a high of $226. In that case, then, we find that the current price level is +80.04% off the targeted high while a plunge would see the stock lose 22.68% from current levels.
Exact Sciences Corporation (EXAS) estimates and forecasts
Figures show that Exact Sciences Corporation shares have outperformed across the wider relevant industry. The company’s shares have gained +4.17% over the past 6 months, with this year growth rate of 38.15%, compared to 8.1% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are -45.1% and -41.4% for the next quarter. Revenue growth from the last financial year stood is estimated to be +15.5%.
16 analysts offering their estimates for the company have set an average revenue estimate of $388.57 Million for the current quarter. 15 have an estimated revenue figure of $413.5 Million for the next quarter concluding in June 01, 2021. Year-ago sales stood $347.82 Million and $268.87 Million respectively for this quarter and the next, and analysts expect sales will grow by 11.7% for the current quarter and 53.8% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -26.8% over the past 5 years. Earnings growth for 2021 is a modest -777.4%.
Exact Sciences Corporation (NASDAQ:EXAS)’s Major holders
Insiders own 0.88% of the company shares, while shares held by institutions stand at 93.01% with a share float percentage of 93.84%. Investors are also buoyed by the number of investors in a company, with Exact Sciences Corporation having a total of 845 institutions that hold shares in the company. The top two institutional holders are Price (T.Rowe) Associates Inc with over 16.55 Million shares worth more than $2.19 Billion. As of December 30, 2020, Price (T.Rowe) Associates Inc held 9.66% of shares outstanding.
The other major institutional holder is Vanguard Group Inc. (The), with the holding of over 14.2 Million shares as of December 30, 2020. The firm’s total holdings are worth over $1.88 Billion and represent 8.29% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Price (T.Rowe) New Horizons Fund and Growth Fund Of America Inc. As of December 30, 2020, the former fund manager holds about 3.36% shares in the company for having 5762950 shares of worth $763.53 Million while later fund manager owns 5.17 Million shares of worth $681.53 Million as of March 30, 2021, which makes it owner of about 3.02% of company’s outstanding stock.